ALX Oncology
ALXO
About: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Employees: 49
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
586% more call options, than puts
Call options by funds: $48K | Put options by funds: $7K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
10.75% less ownership
Funds ownership: 65.2% [Q1] → 54.45% (-10.75%) [Q2]
28% less funds holding
Funds holding: 85 [Q1] → 61 (-24) [Q2]
43% less capital invested
Capital invested by funds: $22.1M [Q1] → $12.6M (-$9.55M) [Q2]
71% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 34
72% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 32
Financial journalist opinion
Based on 3 articles about ALXO published over the past 30 days
